GlassScriptPhysician profile
Emilie Riddle
NPI 1457526972
$3,383.54
in general payments reported to CMS, 2019-2025
28 companies · $341 in 2025
The $341 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $636 · 2020: $373 · 2021: $125 · 2022: $587 · 2023: $695 · 2024: $626 · 2025: $341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,662.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,662.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $612.51 | 2019-2025 | Shingrix, Arexvy |
| Exact Sciences Corporation | $470.66 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $375.18 | 2020-2024 | Breztri, Andexxa |
| Amgen INC. | $368.67 | 2019-2025 | Evenity, Prolia |
| Abbott Laboratories | $335.82 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $322.75 | 2019-2024 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Pfizer INC. | $125.30 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.79 | 2019-2022 | |
| Sanofi Pasteur INC. | $90.21 | 2019-2022 | |
| Astellas Pharma US INC | $86.64 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $67.88 | 2022 | |
| Lilly USA, LLC | $56.68 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $40.55 | 2022 | |
| Collegium Pharmaceutical, INC. | $38.98 | 2019 | |
| Biogen, INC. | $32.60 | 2019-2024 | Spinraza |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $32.22 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Novo Nordisk INC | $28.97 | 2019 | |
| Sanofi-Aventis U.S. LLC | $27.96 | 2019 | |
| Amarin Pharma, INC. | $16.98 | 2019 | |
| Smith+Nephew, INC. | $16.32 | 2024 | Renasys, Acticoat 4" X 4" |
| Medtronic, INC. | $15.95 | 2024 | Intellis Adaptivestim |
| Bausch Health US, LLC | $15.34 | 2020 | |
| Mannkind Corporation | $15.25 | 2023 | Afrezza |
| Allergan, INC. | $14.63 | 2019 | |
| Organon LLC | $13.81 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.51 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $13.02 | 2023 | Uptravi, Opsumit |
| Daiichi Sankyo INC. | $12.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emilie Riddle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.